Sensorion (ALSEN) Stock Overview

A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. More details

ALSEN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 57.14% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Volatile share price over the past 3 months compared to the French market

Currently unprofitable and not forecast to become profitable over the next 3 years

ALSEN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW432,504 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

432,504 investors already sharing narratives

View all narratives

Sensorion SA Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sensorion
Historical stock prices
Current Share Price	€8.63
52 Week High	€40.40
52 Week Low	€8.63
Beta	0.41
1 Month Change	-37.24%
3 Month Change	-30.40%
1 Year Change	-44.32%
3 Year Change	-75.34%
5 Year Change	-91.34%
Change since IPO	-96.20%

Recent updates

Analysis Article • Dec 02

Does Sensorion (EPA:ALSEN) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Analysis Article • Sep 26

Companies Like Sensorion (EPA:ALSEN) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysis Article • Mar 20

Did The Underlying Business Drive Sensorion's (EPA:ALSEN) Lovely 310% Share Price Gain?

Sensorion SA ( EPA:ALSEN ) shareholders have seen the share price descend 19% over the month. But that cannot eclipse...

Shareholder Returns

	ALSEN	FR Biotechs	FR Market
7D	-20.6%	-8.0%	-1.3%
1Y	-44.3%	15.6%	-1.9%

Return vs Industry: ALSEN underperformed the French Biotechs industry which returned 15.6% over the past year.

Return vs Market: ALSEN underperformed the French Market which returned -1.9% over the past year.

Price Volatility

Is ALSEN's price volatile compared to industry and market?
ALSEN volatility
ALSEN Average Weekly Movement	7.0%
Biotechs Industry Average Movement	6.9%
Market Average Movement	4.2%
10% most volatile stocks in FR Market	8.6%
10% least volatile stocks in FR Market	2.1%

Stable Share Price: ALSEN's share price has been volatile over the past 3 months compared to the French market.

Volatility Over Time: ALSEN's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

Founded	Employees	CEO	Website
2009	63	Fred Chereau	www.sensorion.com

Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials.

Sensorion SA Fundamentals Summary

How do Sensorion's earnings and revenue compare to its market cap?
ALSEN fundamental statistics
Market cap	€88.84m
Earnings (TTM)	-€29.43m
Revenue (TTM)	€5.81m

15.3x

P/S Ratio

-3.0x

P/E Ratio

Is ALSEN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALSEN income statement (TTM)
Revenue	€5.81m
Cost of Revenue	€0
Gross Profit	€5.81m
Other Expenses	€35.24m
Earnings	-€29.43m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-2.86
Gross Margin	100.00%
Net Profit Margin	-506.17%
Debt/Equity Ratio	1.7%

How did ALSEN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/21 00:08
End of Day Share Price	2026/09/21 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sensorion SA is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jack Allen	Baird
Janani Sundararajan	Chardan Capital Markets, LLC
Yevgeniya Livshits	Chardan Capital Markets, LLC

Sensorion (ALSEN) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Sensorion SA Competitors

ABIONYX Pharma

Adocia

Eurobio Scientific Société anonyme

Cellectis

Price History & Performance

Recent News & Updates

Sensorion Announces Registration And Connection Details For SENS-601 Program Day And Provides Updates On SENS-601 And SENS-401 Product Pipeline

Consensus revenue estimates fall by 71%

New major risk - Revenue and earnings growth

Sensorion Receives Clinical Trial Authorization in France for SENS-601 Gene Therapy for Gjb2-Related Hearing Loss

Price target decreased by 8.3% to €1.14

Sensorion Achieves Key Regulatory Milestones for Sens-601 for Gjb2-Related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Recent updates

Sensorion Announces Registration And Connection Details For SENS-601 Program Day And Provides Updates On SENS-601 And SENS-401 Product Pipeline

Consensus revenue estimates fall by 71%

New major risk - Revenue and earnings growth

Sensorion Receives Clinical Trial Authorization in France for SENS-601 Gene Therapy for Gjb2-Related Hearing Loss

Price target decreased by 8.3% to €1.14

Sensorion Achieves Key Regulatory Milestones for Sens-601 for Gjb2-Related Hearing Loss and Selects Program as Lead Gene Therapy Candidate

Consensus EPS estimates upgraded to €0.015 loss

Sensorion SA Announces Chief Executive Officer Changes

Sensorion SA, Annual General Meeting, May 11, 2026

New major risk - Revenue and earnings growth

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Price target decreased by 23% to €1.30

Sensorion Reports Six-Month Update from the Audiogene Phase 1/2 Trial of SENS-501 and Advances GJB2-GT (SENS-601) Toward First-In-Human Clinical Development

New minor risk - Profitability

Forecast to breakeven in 2026

Consensus revenue estimates fall by 57%

New major risk - Revenue and earnings growth

Sensorion Sa Announces Stepping Down of Nawal Ouzren as Director on the Board

New major risk - Share price stability

New minor risk - Profitability

Forecast to breakeven in 2026

Sensorion SA has filed a Follow-on Equity Offering in the amount of €60 million.

New minor risk - Market cap size

Sensorion Reports Independent Data Monitoring Committee Raises No Safety Concerns and Agrees to Continue SENS-501'S Audiogene Phase 1/2 Trial

Consensus revenue estimates increase by 22%

Price target increased by 12% to €2.38

Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial

Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial

New minor risk - Market cap size

Consensus revenue estimates increase by 49%

Sensorion SA, Annual General Meeting, May 12, 2025

Sensorion Announces Board Changes

New minor risk - Share price stability

Consensus revenue estimates increase by 26%

Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of Sens-401 for the Prevention of Cisplatin-Induced Ototoxicity

Sensorion Receives Positive Recommendation from Data Monitoring Committee of Sens-501’S Audiogene Phase 1/2 Clinical Trial

Price target increased by 7.1% to €2.50

Sensorion Announces Completion of Enrollment of the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial

Sensorion Reports Data in the Audiogene Phase 1/2 Gene Therapy Clinical Trial

Does Sensorion (EPA:ALSEN) Have A Healthy Balance Sheet?

Consensus revenue estimates increase by 13%

First half 2024 earnings released

Sensorion Announces Positive Recommendation From the Data Safety Monitoring Board (DSMB) Regarding the Continuation of NOTOXIS, its Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity

Sensorion Announces New Positive Secondary Efficacy Endpoints Data from Sens-401 Phase 2A Clinical Trial for the Preservation of Residual Hearing Loss

Sensorion Announces Appointment of Laurene Danon as Chief Financial Officer

New major risk - Revenue and earnings growth

Sensorion SA, Annual General Meeting, May 29, 2024

Sensorion SA has completed a Follow-on Equity Offering in the amount of €15.482057 million.

Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation

Sensorion SA to Report Fiscal Year 2023 Results on Mar 14, 2024

Sensorion Announces the Completion of Patient Inclusion in Phase 2A Clinical Trial of Sens-401 for Residual Hearing Preservation After Cochlear Implantation

Sensorion Appoints Federico Mingozzi as Non-Executive Director to the Board of Directors

Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate Sens-501 into a Phase 1/2 Clinical Trial in Some European Countries

Consensus revenue estimates increase by 15%

Sensorion SA Appoints Bernd Schmidt as New Chief Technical Officer

Sensorion SA, Annual General Meeting, Dec 20, 2023

New minor risk - Market cap size

Consensus revenue estimates increase by 242%

Sensorion SA announced that it has received €33.214286 million in funding from Sofimac Innovation SAS, The Invus Group, LLC, Redmile Group, LLC

Price target decreased by 14% to €2.33

New major risk - Revenue and earnings growth